ȼøÀü³²´ëº´¿ø ¾ÈÀç¼÷¡¤±è¹ÌÈñ ±³¼ö, ±¹Á¦Çмú´ëȸ ÃÖ¿ì¼ö±¸¿¬»ó ȼø±Û·Î¹ú´º½º 3710612@naver.com |
2024³â 10¿ù 07ÀÏ(¿ù) 15:01 |
|
ȼøÀü³²´ëÇб³º´¿ø Ç÷¾×³»°ú ¾ÈÀç¼÷¡¤±è¹ÌÈñ ±³¼ö°¡ ¡®Á¦8Â÷ ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ ¹× Á¦29Â÷ Á¤±âÃÑȸ(ICBMT 2024)¡¯¿¡¼ °¢°¢ ÃÖ¿ì¼ö±¸¿¬»óÀ» ¼ö»óÇß´Ù.
¾ÈÀç¼÷ ±³¼ö´Â ¡®±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚ¿¡¼ ¿¹ÈÄ ÁöÇ¥·Î¼ÀÇ Áø´Ü NGS ÆгΠ±â¹Ý ¿¬¼Ó ÃøÁ¤ °¡´ÉÇÑ ¹Ì¼¼ÀÜÁ¸¾Ï ¸ð´ÏÅ͸µ(Diagnostic NGS Panel-Based Serial Measurable Residual Disease Monitoring as a Prognostic Indicator in Acute Myeloid Leukemia Patients) Á¦¸ñÀÇ ³í¹®À» ¹ßÇ¥Çß´Ù.
¾È ±³¼ö´Â ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚÀÇ À¯Àü¼º Ư¡ ºÐ¼® ¹× º¸´Ù Á¤È®ÇÑ ÁúȯÀÇ ¿¹ÈÄ ¿¹Ãø¿¡ ±â¿©Çß´Ù´Â Æò°¡¸¦ ¹Þ¾Ò´Ù.
¶Ç ±è¹ÌÈñ ±³¼ö´Â ¡®³ëÀαâ´ÉÆò°¡¸¦ ÀÌ¿ëÇÑ Àú¸ÞÆ¿ÈÄ¡·á¸¦ ±â¹ÝÀ¸·Î Ä¡·á¹ÞÀº °í·ÉÀÇ °ñ¼ö¼º Áúȯ ȯÀÚÀÇ Á¶±â»ç¸Á ¿¹Ãø(Early Prediction of Hypomethylating Agent Based Therapy Outcome in Elderly Myeloid Disease Patients:A Geriatric Functional Assessment Approach) Á¦¸ñÀÇ ³í¹®À» ÅëÇØ ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.
±è ±³¼ö´Â ³í¹®À» ÅëÇØ °í·É ȯÀÚÀÇ °æ¿ì °í°µµ Ä¡·á¿¡ ÀûÇÕÇÑ È¯ÀÚ¸¦ ¼±º°ÇÏ´Â ±âÁØ¿¡ ¸íÈ®ÇÏÁö ¾Ê¾Æ ȯÀÚµéÀÌ ÃæºÐÇÑ Ä¡·á¸¦ ¹ÞÁö ¸øÇÏ´Â °æ¿ì°¡ ÀÖ´Ù´Â °ÍÀ» È®ÀÎÇÏ°í, ÀÌ¿¡ Áø´Ü ½Ã ³ëÀαâ´ÉÆò°¡¸¦ ÅëÇØ Ä¡·á¿¡ ÀûÇÕÇÑ È¯ÀÚ±º ¼±º° ±âÁØÀ» Á¦½ÃÇÒ ¼ö ÀÖ´Â ¿¬±¸ °á°ú¸¦ ÀÔÁõÇØ ³Â´Ù.
±è¹ÌÈñ ±³¼ö´Â ¡°ÇØ´ç ¿¬±¸¸¦ ÅëÇØ °ñ¼ö°è Ç÷¾×¾Ï ȯÀÚÀÇ ¿¹ÈÄ °³¼±¿¡ µµ¿òÀÌ µÉ °ÍÀÌ´Ù¡±°í ¸»Çß´Ù.
ÇÑÆí ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ´Â 2017³âºÎÅÍ °³ÃÖÇÏ°í ÀÖÀ¸¸ç ¸Å³â 30¿© °³±¹¿¡¼ 1,000¿© ¸íÀÇ Âü°¡ÀÚµéÀÌ ÇÑÀÚ¸®¿¡ ¸ð¿© Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¹× ¼¼Æ÷Ä¡·á ºÐ¾ßÀÇ ÃֽŠ¿¬±¸¼º°ú¸¦ °øÀ¯ÇÏ°í ÀÖ´Ù.
ȼø±Û·Î¹ú´º½º 3710612@naver.com